GT Biopharma Inc GTBP 深 滬
已收盤 02-06 16:00:00 美东时间
0.5389
+0.042
+8.54%
華盛通- 最 高0.54
- 今 開0.48
- 成交量 97.54万股
- 最 低 0.4548
- 昨 收 0.4965
- 總市值 1436.29万
- 52周最高 3.85
- 市盈率 靜 --
- 換手率 3.66%
- 52周最低 0.4011
- 委 比 68.62%
- 總股本 2665.22万
- 歷史最高 591.99
- 量 比 0.32
- 振 幅 17.16%
- 歷史最低 0.4011
- 每 手 1
- 風險率 0.87%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BUZZ-U.S. STOCKS ON THE MOVE-JetBlue, VSE, Walt Disney
BUZZ-U.S. STOCKS ON THE MOVE-JetBlue, VSE, Walt Disney Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The S&P 500 and the Nasdaq looked set for a firm open on Tuesday, stabilizing a
02-03 22:17
GT Biopharma Receives FDA Clearance Of Investigational New Drug Application For GTB-5550 TriKE
GTB-5550 Phase 1 dose escalation basket trial expected to initiate mid-2026Phase 1 protocol allows multiple solid tumor types known to express B7-H3Unaudited proforma cash balance as of January 31, 2026 of approximately
02-03 21:33
GT Biopharma Receives FDA Clearance for IND Application of GTB-5550 TriKE
GT Biopharma Receives FDA Clearance for IND Application of GTB-5550 TriKE GT Biopharma Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for GTB-5550, a B7-H3-targeted natural killer (NK) cell engager for solid tumors expressin
02-03 21:30
GT Biopharma erhält FDA-Zulassung für IND-Antrag zu GTB-5550
GT Biopharma erhält FDA-Zulassung für IND-Antrag zu GTB-5550 GT Biopharma Inc. hat die Zulassung der US-amerikanischen FDA für die Durchführung einer Phase-1-Studie mit GTB-5550, einem B7-H3-gerichteten NK-Zell-Engager für solide Tumoren, erhalten. Die Studie ist als Basket-Studie konzipiert und sol
02-03 21:30
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3
GT Biopharma received FDA clearance for its IND application for GTB-5550, a novel TriKE® NK cell engager targeting B7-H3-expressing solid tumors. The Phase 1 trial, expected to begin mid-2026, will evaluate safety and efficacy in advanced prostate, ovarian, and pancreatic cancer patients who have failed standard therapies. GTB-5550 uses a dual nanobody approach with subcutaneous dosing, and the trial will assess up to 6 dose levels before moving ...
02-03 13:30
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers AstraZeneca PLC Ordinary Shares (NYSE:AZN) stock rose 107.1% to $192.1...
02-03 01:05
Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape
Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Jan. 16, 2026 /PRNewswire/ -- Equity Insider News Commentary – The precision medicine sector is undergoing a structural realignment towa...
01-16 21:00
EXCLUSIVE: GT Biopharma Plans 2026 Trial For New Cancer Treatment
GT Biopharma submitted an IND application for GTB-5550 TriKE for solid tumors. Phase 1 trial planned for 2026.
01-15 21:01
EXCLUSIVE: GT Biopharma Announces IND Submission For GTB-5550 TriKE; Reports Preliminary Unaudited Cash Balance Of ~$7M As Of Dec. 31, 2025
GT Biopharma targets a portion of the estimated $362 billion global solid tumor market with its B7-H3 TrikePreliminary, unaudited cash balance of approximately $7 million as of December 31, 2025 anticipated to extendGT Biopharma targets a portion of the estimated $362 billion global solid tumor market with its B7-H3 Trike
01-15 21:00
GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers
GT Biopharma submitted an IND application for GTB-5550, a B7-H3-targeted NK cell engager, to treat B7-H3-expressing solid tumors. The company aims to initiate a Phase 1 basket trial in 2026. GTB-5550 uses a TriKE platform combining anti-CD16, WT IL-15, and anti-B7-H3 nanobodies to activate NK cells. The trial will assess safety and tolerability across seven cancer types, with subcutaneous dosing over five days per week. The global market for B7-H...
01-15 13:30
